Dados B3 › SRNA3 × EGIE3 · Português
Each row uses the most recent year in which BOTH companies have the figure, and says which year that is. A cell with ! carries a caveat — hover to read it. We do not name a winner: that would be a recommendation, and this site does not give any.
| indicator | SRNA3 | EGIE3 | year |
|---|---|---|---|
| ROE | 0.2% | 21.5% | 2025 |
| ROIC | 4.1%! | 13.9% | 2025 |
| ROA | 0.1% | 5.4% | 2025 |
| Gross margin | 17.1% | 46.7% | 2025 |
| EBIT margin | 18.7% | 48.7% | 2025 |
| Net margin | 0.3% | 22.2% | 2025 |
| Net debt/EBITDA | 5.18x | 3.30x | 2025 |
| Current ratio | 1.29x | 1.12x | 2025 |
| Revenue growth (1y) | 60.4% | 14.6% | 2025 |
| Revenue growth (5y CAGR) | — | 1.0% | no year where both have it |
| Piotroski F-Score | 7/9 | 5/9 | 2025 |
Priced at the first session on or after the day each filing became public — never the period close.
| indicator | SRNA3 | EGIE3 | year |
|---|---|---|---|
| P/E | 16.60x | 14.21x | 2024 × 2025 |
| P/B | 0.88x | 2.88x | 2024 × 2025 |
| EV/EBITDA | 6.78x | 8.09x | 2024 × 2025 |
| FCF yield | 0.4% | 4.3% | 2024 × 2025 |
Numbers on this page are live. Data version 2026-09-01-supressao-declarada · page generated 2026-09-08 14:49 UTC. If this does not match /saude, you are reading a cached copy.
Home · Methodology · Transparency · Audit it